Clinical Trial Search

Primary: Type 2 Diabetes Mellitus in GH-treated Participants — 1; 9; 8 Incident Cases

Primary: Upper Extremity Fugl-Meyer — 43.8; 21.4; 42.8; 21.5 score on a scale — p=.443

Primary: Western Ontario McMaster (WOMAC) Osteoarthritis Index Pain — 84.0; 78.3 units on a scale

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 95.2; 9.5 percentage of participants

Primary: Change in Severity of Psychotic Symptoms — 20.20; 19.88; 21.98; 20.96 units on a scale — p=.85

Primary: Counts of Participants With Successful H. Pylori Eradication — 146; 134 Participants

Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001

Primary: Comparison of Change in Chronic Sinusitis Survey (CSS) Score at 24 Weeks Compared to Baseline — 41.9; 27.0 Scores on a scale

Primary: Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority) — 82; 87; 82; 83 Participants

Primary: Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12 — 142; 147 participants

Primary: Postprandial Glucose Area Under the Curve (AUC) — 1341; 1463 mmol/L*t

Primary: Number of Participants With Adverse Drug Reactions and Serious Adverse Drug Reactions — 276; 74 Participants

Primary: Safety of Fresh, Frozen or Lyophilized Intestinal Bacteria From Healthy Donors Given by Colonoscopy for Therapy in Subjects With Recurrent C. Difficile Associated…

Primary: Peak Plantar Pressure — 75.3; 14.2; 14.5; 22.8 Newtons per squared centimeters

Primary: Questionnaire: Quality of Recovery 40 — 174; 167 score on a scale